2022欧洲心脏病学会(ESC)肿瘤心脏病学指南--高血压相关内容解读  

2022 ESC Guidelines on Cardio-Oncology:Interpretation of Hypertension

作　　者：褚紫昕 匡泽民 刘佐军[1] 温宇梅[1] CHU Zi-xin;KUANG Ze-min;LIU Zuo-jun;WEN Yu-mei(Department of Health Care Ward,Beijing Luhe Hospital,Capital Medical University,Beijing 101100,China;Hypertension Center of Department of Cardiology,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)

机构地区：[1]首都医科大学附属北京潞河医院医疗保健病区,北京101100 [2]首都医科大学附属北京安贞医院心内科高血压中心,北京100029

出　　处：《中国合理用药探索》2023年第4期37-41,共5页Chinese Journal of Rational Drug Use

基　　金：北京市自然科学基金面上专项(M22009)。

摘　　要：肿瘤的发病率逐年升高,而随着医疗条件及肿瘤诊治水平的提高,肿瘤患者生存率也提高,但肿瘤治疗相关心脏毒性也逐步显现。对肿瘤幸存者来说,心血管疾病已成为危害生命健康的第二大杀手,仅次于复发性恶性肿瘤。而高血压是一种在肿瘤患者中发病率高又容易被忽视的心血管疾病。肿瘤相关高血压作为一个新兴的亚领域,其防治标准尚未统一。2022年8月欧洲心脏病学会(ESC)发布了第1个肿瘤心脏病学指南。本文从肿瘤相关高血压角度出发,对肿瘤心脏病学指南进行解读。该指南明确了导致肿瘤相关高血压的肿瘤治疗方案、定义了肿瘤相关高血压的治疗标准、提出了肿瘤相关高血压药物选择的原则并提供了肿瘤相关高血压监测和管理的建议,旨在帮助医疗专业人员对肿瘤相关高血压进行监测,以期减少心脏毒性,保证肿瘤治疗顺利进行,降低死亡率。The incidence of cancer is increasing year by year.With the improvement of medical conditions and the level of cancer diagnosis and treatment,the survival rate of cancer patients is also increasing,but the cardiotoxicity associated with cancer treatment has also gradually emerged.For cancer survivors,cardiovascular disease has become the second major killer,next to recurrent malignant tumors.Hypertension is a cardiovascular disease with high incidence and easy to be ignored in cancer patients.Cancer-associated hypertension is a new subfield,and its prevention and treatment standards have not yet been standardized.In August 2022,the European Society of Cardiology(ESC)issued the first guideline on cardio-oncology.This article interprets the guideline on cardio-oncology from the perspective of cancer-associated hypertension.The guideline clarifies the cancer treatment regimens leading to cancer-associated hypertension,defines the treatment standard for cancer-associated hypertension,proposes the principles of drug selection for cancerassociated hypertension,and provides recommendations for the monitoring and management of cancerassociated hypertension.The aim of this study is to help medical professionals to monitor cancer-associated hypertension in order to reduce cardiotoxicity,ensure successful treatment of cancer,and reduce mortality.

关 键 词：肿瘤心脏病学 肿瘤相关高血压 血管内皮生长因子抑制剂 血压管理 指南解读 

分 类 号：R544.1[医药卫生—心血管疾病]